Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL (clinicaltrials.gov) - Sep 30, 2026 - P1/2 | N=40 | Not yet recruiting | Sponsor: Dana-Farber Cancer Institute
New P1/2 trial • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology
|